Detection of Hepatic Metastases Using Dual-Time-Point FDG PET/CT Scans in Patients with Colorectal Cancer

Taylor I (1996) Liver metastases from colorectal cancer: lessons from past and present clinical studies. Br J Surg 83:456–460 Gayowski TJ, Iwatsuki S, Madariaga JR et al (1994) Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery 116:703–710 Jatzko GR, Lisborg PH, Stettner HM, Klimpfinger MH (1995) Hepatic resection for metastases from colorectal carcinoma–a survival analysis. Eur J Cancer 31A:41–46 Nakamura S, Suzuki S, Baba S (1997) Resection of liver metastases of colorectal carcinoma. World J Surg 21:741–747 Scheele J, Stangl R, Altendorf-Hofmann A, Gall FP (1991) Indicators of prognosis after hepatic resection for colorectal secondaries. Surgery 110:13–29 Delbeke D, Vitola JV, Sandler MP et al (1997) Staging recurrent metastatic colorectal carcinoma with PET. J Nucl Med 38:1196–1201 Zhuang H, Sinha P, Pourdehnad M, Duarte PS, Yamamoto AJ, Alavi A (2000) The role of positron emission tomography with fluorine-18-deoxyglucose in identifying colorectal cancer metastases to liver. Nucl Med Commun 21:793–798 Rappeport ED, Loft A, Berthelsen AK et al (2007) Contrast-enhanced FDG-PET/CT vs. SPIO-enhanced MRI vs. FDG-PET vs. CT in patients with liver metastases from colorectal cancer: a prospective study with intraoperative confirmation. Acta Radiol 48:369–378 Kim BI (2008) Clinical application of F-18 FDG PET (PET/CT) in colo-rectal and anal cancer. Nucl Med Mol Imaging 42(Supple):52–59 Bipat S, van Leeuwen MS, Comans EF et al (2005) Colorectal liver metastases: CT, MR imaging, and PET for diagnosis–meta-analysis. Radiology 237:123–131 Ruers TJ, Langenhoff BS, Neeleman N et al (2002) Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study. J Clin Oncol 20:388–395 Brix G, Ziegler SI, Bellemann ME et al (2001) Quantification of [(18)F]FDG uptake in the normal liver using dynamic PET: impact and modeling of the dual hepatic blood supply. J Nucl Med 42:1265–1273 Kubota K, Itoh M, Ozaki K et al (2001) Advantage of delayed whole-body FDG-PET imaging for tumour detection. Eur J Nucl Med 28:696–703 Zhuang H, Pourdehnad M, Lambright ES et al (2001) Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med 42:1412–1417 Yen RF, Chen KC, Lee JM et al (2008) 18F-FDG PET for the lymph node staging of non-small cell lung cancer in a tuberculosis-endemic country: is dual time point imaging worth the effort? Eur J Nucl Med Mol Imaging 35:1305–1315 Kumar R, Loving VA, Chauhan A, Zhuang H, Mitchell S, Alavi A (2005) Potential of dual-time-point imaging to improve breast cancer diagnosis with (18)F-FDG PET. J Nucl Med 46:1819–1824 Nishiyama Y, Yamamoto Y, Fukunaga K et al (2006) Dual-time-point 18F-FDG PET for the evaluation of gallbladder carcinoma. J Nucl Med 47:633–638 Inoue A, Tomiyama N, Tatsumi M et al (2009) (18)F-FDG PET for the evaluation of thymic epithelial tumors: Correlation with the World Health Organization classification in addition to dual-time-point imaging. Eur J Nucl Med Mol Imaging 36:1219–1225 Koyama K, Okamura T, Kawabe J et al (2002) The usefulness of 18F-FDG PET images obtained 2 hours after intravenous injection in liver tumor. Ann Nucl Med 16:169–176 Lin WY, Tsai SC, Hung GU (2005) Value of delayed 18F-FDG-PET imaging in the detection of hepatocellular carcinoma. Nucl Med Commun 26:315–321 Dirisamer A, Halpern BS, Schima W et al (2008) Dual-time-point FDG-PET/CT for the detection of hepatic metastases. Mol Imaging Biol 10:335–340 Chen YK, Kao CH (2005) Metastatic hepatic lesions are detected better by delayed imaging with prolonged emission time. Clin Nucl Med 30:455–456 Kuker RA, Mesoloras G, Gulec SA (2007) Optimization of FDG-PET/CT imaging protocol for evaluation of patients with primary and metastatic liver disease. Int Semin Surg Oncol 4:17 Arena V, Skanjeti A, Casoni R, Douroukas A, Pelosi E (2008) Dual-phase FDG-PET: delayed acquisition improves hepatic detectability of pathological uptake. Radiol Med 113:875–886 Hamberg LM, Hunter GJ, Alpert NM, Choi NC, Babich JW, Fischman AJ (1994) The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? J Nucl Med 35:1308–1312 Masuda Y, Kondo C, Matsuo Y, Uetani M, Kusakabe K (2009) Comparison of imaging protocols for 18F-FDG PET/CT in overweight patients: optimizing scan duration versus administered dose. J Nucl Med 50:844–848 Halpern BS, Dahlbom M, Auerbach MA et al (2005) Optimizing imaging protocols for overweight and obese patients: a lutetium orthosilicate PET/CT study. J Nucl Med 46:603–607 Tamaki T, Naito A, Nishio M, Kawahara K (2004) FDG-PET for evaluation of recurrent lymph node metastases in patients with surgically resected breast cancer: adding spot images to whole body images. Breast Cancer 11:60–64 Chin BB, Green ED, Turkington TG, Hawk TC, Coleman RE (2009) Increasing uptake time in FDG-PET: standardized uptake values in normal tissues at 1 versus 3 h. Mol Imaging Biol 11:118–122 Ruers TJ, Wiering B, van der Sijp JR et al (2009) Improved selection of patients for hepatic surgery of colorectal liver metastases with (18)F-FDG PET: a randomized study. J Nucl Med 50:1036–1041 Matthies A, Hickeson M, Cuchiara A, Alavi A (2002) Dual time point 18F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med 43:871–875 Suga K, Kawakami Y, Hiyama A et al (2009) Dual-time point 18F-FDG PET/CT scan for differentiation between 18F-FDG-avid non-small cell lung cancer and benign lesions. Ann Nucl Med 23:427–435 Chen YM, Huang G, Sun XG et al (2008) Optimizing delayed scan time for FDG PET: comparison of the early and late delayed scan. Nucl Med Commun 29:425–430